Stock Analiz

Evaxion A EVAX

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$2.74Market cap $25M
Open the interactive analysis →

Evaxion A (EVAX) is a healthcare company listed in the US with a market value of about $25M. In the twelve months to June 30, 2026 it had revenue of $7M and net income of -$9M, a net margin of -115.5%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -204%.

About Evaxion A

Evaxion A is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 8 years in our data.

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.4
P/B2.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-28.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)125.1%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-10242.2%
ROIC (5-yr avg.)-204.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$7M$8M$3M$73000$0————
Net income-$9M-$8M-$11M-$22M-$23M-$25M-$15M-$11M-$6M
Free cash flow-$7M-$7M-$13M-$18M-$26M-$23M-$13M-$7M-$2M
EPS (diluted)$-1.04$-0.84$-1.15$-2.40$-2.51$-2.66$-1.63$-1.21$-0.60
Net margin-115.5%-102.4%-316.0%-30308.2%—————
ROIC—-36.6%-210.4%-546.9%-150.0%-76.3%-213.3%-108.1%-65.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $12.25, 347% above the current price; targets range from $9.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-0.04 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Evaxion A pay a dividend?

Not currently.

Is Evaxion A a good stock to buy?

We do not give buy or sell advice. Evaxion A scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.